Canada - English - Health Canada

emd serono, a division of emd inc., canada - follitropin alfa - solution - 900unit - follitropin alfa 900unit - gonadotropins and antigonadotropins

Canada - English - Health Canada

emd serono, a division of emd inc., canada - follitropin alfa - solution - 450unit - follitropin alfa 450unit - gonadotropins and antigonadotropins

Canada - English - Health Canada

emd serono, a division of emd inc., canada - follitropin alfa - solution - 300unit - follitropin alfa 300unit - gonadotropins and antigonadotropins

United States - English - NLM (National Library of Medicine)

emd serono, inc. - follitropin (unii: 076whw89tw) (follitropin - unii:076whw89tw) - follitropin 300 [iu] in 0.5 ml - prior to initiation of treatment with gonal-f® rff redi-ject® : - perform a complete gynecologic and endocrinologic evaluation - exclude primary ovarian failure - exclude the possibility of pregnancy - demonstrate tubal patency - evaluate the fertility status of the male partner prior to initiation of treatment with gonal-f® rff redi-ject® : - perform a complete gynecologic and endocrinologic evaluation, and diagnose the cause of infertility - exclude the possibility of pregnancy - evaluate the fertility status of the male partner gonal-f® rff redi-ject® is contraindicated in women who exhibit: - prior hypersensitivity to recombinant fsh products - high levels of fsh indicating primary gonadal failure - pregnancy gonal-f® rff redi-ject® may cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)] . gonal-f® rff redi-ject® is contraindicated in women who are pregnant. if this drug is used during pregnancy, or if the woman becomes pregnant while taking

Israel - English - Ministry of Health

truemed ltd, israel - follitropin alfa - solution for injection - follitropin alfa 600 iu / 1 ml - follitropin alfa - in adult women:• anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate.• stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra fallopian transfer (zift).• ovaleap in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l.in adult men:• ovaleap is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hcg) therapy.

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - follitropin alfa - injection, powder, for solution - 5.5 mcg/vial - follitropin alfa 75iu (5.5mcg) /vial

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - follitropin alfa - injection, powder, for solution - 600 iu/ml - follitropin alfa 600 iu/ml

Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - corifollitropin alfa - injection, solution - 0.100mg - corifollitropin alfa 0.100mg

Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - corifollitropin alfa - injection, solution - 0.150mg - corifollitropin alfa 0.150mg

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - follitropin alfa (r-hfsh); lutropin alfa (r-hlh) - injection, powder, for solution - 150 iu - follitropin alfa (r-hfsh) 150 iu; lutropin alfa (r-hlh) 75 iu